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ABSTRACT                     Modulation of the sensory input can occur within the dorsal horn of the spinal
cord where the primary afferent fibers synapse with neurons that transmit to the higher
centers. The transmission of the sensory information begins with activation of the peripheral
receptors of primary afferent neurons whose cell bodies lie within the dorsal root ganglia and
whose central terminals project to secondary neurons in the dorsal horn of the spinal cord.
Several neurotransmitters and a large variety of receptors have been found in the superficial
laminae of the dorsal horn. The present work reviews the major classes of transmitters and
receptors that have been implicated in the transmission and modulation of spinal afferent and
pain processing. The role of excitatory and inhibitory amino acids, tachykinin and opioid
peptides, calcitonin gene-related peptide (CGRP), nociceptin and nocistatin, biogenic amines,
acetylcholine, ATP, nitric oxide as well as capsaicin and vanilloid receptors will be discussed
along with the most recent developments in the field. It seems probable that transmission of
the somatosensory information from the primary afferent fibers to the secondary dorsal horn
neurons depends on the balance between the excitatory effects of excitatory amino acids and
the inhibitory actions of several other transmitter systems.
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The transmission of somatosensory information begins with
activation of the peripheral receptors of primary afferent
neurons whose cell bodies lie within the dorsal root ganglia
(DRG) and whose central terminals project to secondary
neurons in the dorsal horn of the spinal cord. In cutaneous
and visceral nerves of the rat, the fastest-conducting large
myelinated sensory fibers belong to the Aβ class; the slower-
conducting, thinly myelinated fibers belong to the Aδ group;
the slowest-conducting unmyelinated small fibers are desig-
nated as C-fibers. A weak electrical stimulus can selectively
activate large myelinated axons. Stronger, and probably
painful, electrical stimuli are required to excite unmyelinated
C-fibers in addition to myelinated axons. While several
compounds have been proposed as endogenous neurotrans-
mitters released from afferent neurons following a nocice-
ptive (painful) stimulus, current evidence implicate the
excitatory amino acids (EAAs), aspartate and glutamate, and
the peptide substance P (SP). For instance, in many of the
convergent nociceptive spinal dorsal horn neurons, repetitive
stimulation of the cutaneous receptive field at a constant
strength great enough to excite C-fibers, causes a progressive
increase in the number of spikes evoked by the successive
arrival of volleys along C-fibers over the first 10-16 stimuli
(Mendell and Wall 1965; Mendell 1966). This frequency-
dependent potentiation is called wind-up and is associated
with the activation of the N-methyl-D-aspartate (NMDA)
receptor complex (Davies and Lodge 1987; Dickenson and
Sullivan 1987; Dickenson 1990; Budai 1994). Release of SP
in response to noxious stimulation may increase primary
afferent C-fiber activity and an accumulation of SP N-
terminal metabolites appears to potentiate wind-up via
positive modulation of EAA activity (Budai and Larson
1996).
The efficiency of synapses in the CNS is not constant, but
can be modified by changing the activity in the presynaptic
pathways. Long-term potentiation (LTP) in the hippocampus,
which may comprise the synaptic basis of learning and
memory, has become the dominant model of activity-depen-
dent synaptic plasticity in the mammalian brain. In the spinal
cord, modifications of the synaptic transmission that outlast
the stimulus or the event triggering them can also occur after
various stimulation procedures or injury. Compelling evi-
dence has accumulated over the last several years, indicating
that central hyperactive states resulting from neuronal plastic
changes within the spinal cord play a critical role in hyper-
algesia associated with nerve injury and inflammation
(Mayer et al. 1999). Synaptic modifications that occur in the
spinal cord as a result of repeated stimulation are habituation,
sensitization and post-tetanic potentiation (Mendell 1984).
The repetitive, low-frequency stimulation of unmyelinated
axons in a peripheral cutaneous nerve can cause a wind-up
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of dorsal horn neuron activity, with a progressive potentiation
of responses to each subsequent stimulus. Modifications of
the synaptic transmission in the spinal cord that last for
prolonged periods can occur after relatively brief injury
discharges or afferent conditioning by various stimulation
procedures. Many sensory abnormalities in pathologic
conditions, including pain, hyperalgesia and allodynia, are
presumably due to the plasticity of the dorsal horn circuits.
Primary hyperalgesia can be explained by the sensitization
of primary afferent fibers whereas secondary hyperalgesia
and allodynia are generally thought to depend on a sensiti-
zation of neurons in the dorsal horn. An increased pain
sensation (hyperalgesia), decreased pain threshold (allo-
dynia) and persistent nociception following peripheral tissue
injury depend both on an increase in the sensitivity of
primary afferent nociceptors at the site of the injury (periph-
eral sensitization), and on an increase in the efficiency of the
synapses between primary afferent fibers and the dorsal horn
neurons (central sensitization) (Yaksh et al. 1999). One of the
most important questions relates to the mechanisms by which
a peripheral stimulation can produce long-lasting modifi-
cations of spinal synapses that are related to acute or chronic
pain. The increase in the postsynaptic response generated at
potentiated synapses could be due to any combinations of
these: (a) presynaptic modifications which result in an
increase in the amount of EAAs and other transmitters
released per impulse, (b) postsynaptic modifications such as
changes in the characteristics of receptor functions, (c) an
extrasynaptic change, such as a reduction in uptake or
metabolism of the released substances, or (d) morphological
modifications.
The aim of this paper is to give an overview of the
neurotransmitters and their receptors that play a major role
in mediation of the somatosensory information in the dorsal
horn of the spinal cord. Given the vastness and clinical
relevance of the field, this paper by no means pretends
completeness. We also refer to reviews that have previously
been published on related subjects such as the induction of
pain (Millan 1999), the localization of transmitters and
receptors in the mammalian dorsal horn and primary afferent
neurons (Todd and Spike 1993; Coggeshall and Carlton
1997), the pharmacology of spinal afferent and pain process-
ing (Wilcox 1991; Coderre 1993; Zieglgansberger and Tolle
1993; Wilcox and Seybold 1997; Fürst 1999), and the
descending or central modulation of spinal pain mechanisms
(Fields et al. 1991; Rudomin et al. 1993; Stamford 1995;
Lima 1996; Sandkühler 1996; Millan 1997; Mason 1999).
Excitatory amino acids (EAAs)
L-Glutamate (Glu) and L-aspartate (Asp) are the major
excitatory neurotransmitters in the central nervous system
(CNS). Glu fulfills several of the criteria for a transmitter
involved in neurotransmission from primary afferent fibers
to secondary spinal dorsal horn neurons. Glu-like immu-
noreactivity has been localized in small DRG neurons and
in terminals in the superficial dorsal horn. Glu is released
after electrical stimulation in a Ca2+-dependent manner.
Further, iontophoretically applied EAA agonists activate
nociceptive projection neurons, and this activation is inhibited
by EAA antagonists such as MK-801, 7-chlorokynurenate
(7-Cl-KYNA) or GYKI 53466 (Budai and Larson 1994). In
behavioral studies, EAA agonists elicit thermal hyperalgesia,
and EAA antagonists block the vocalization elicited by
noxious stimulation. These data implicate a contribution of
EAAs to neurotransmission between primary afferent fibers
and secondary dorsal horn neurons (for reviews see Wilcox
1991; Coderre 1993; Todd and Spike 1993; Urban et al. 1994;
Salt and Eaton 1966; Bennett 2000). EAAs produce their
effects through two broad categories of receptors; ionotropic
and metabotropic Glu receptors. The ionotropic Glu receptors
have been traditionally classified into three subtypes upon
the basis of pharmacological and electrophysiological data:
N-methyl-D-aspartate (NMDA) receptors, (R,S)-α-amino-3-
hydroxy-5-methylisoxazole-4-propionate (AMPA) receptors
and kainic acid (KA) receptors. Ionotropic Glu receptors
directly regulate the opening of ion channels to Na+ and K+,
while NMDA receptors do so to Ca2+ as well. A family of G-
protein-coupled Glu receptors, called metabotropic Glu
receptors, has recently been identified. Their activation causes
an increase in the turnover of polyphosphoinositides and in
the release of Ca2+ from intracellular stores.
The application of molecular cloning technology to study
of the Glu receptor system has led to an explosion of knowl-
edge about the structure, expression and function of iono-
tropic and metabotropic Glu receptors. When sequence
homologies as well as pharmacological properties are taken
into account, the 28 Glu receptor genes that have so far been
characterized on a molecular basis can be grouped into 13
subfamilies, 10 for the ionotropic receptor class and 3 for the
metabotropic receptor class. Interestingly, on the basis of
phylogenetic tree of ionotropic and metabotropic Glu re-
ceptors, it appears unprobable that the two families of
receptors share a common ancestor gene. Any sequence
similarity may reflect evolutionary convergence rather than
evolutionary relatedness. Glu receptor subfamilies can also
be grouped according to their pharmacological properties as
follows (for reviews see Hollmann and Heinemann 1994;
Bettler and Mulle 1995; Pin and Duvoisin 1995; Roberts
1995):
AMPA receptors: GluR1-GluR4
These subunits each form homomeric ion channels when
expressed in oocytes or in transfected cells. Agonist potencies
follow the sequence quisqualate>domoate~AMPA>Glu>KA.
Although AMPA is the most potent specific agonist, KA
elicits the largest responses because it does not desensitize
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the receptors. The co-expression of two or more subunits
does not alter the order of agonist potency, although poten-
cies are generally lower in heteromeric receptors. Both
homomeric and heteromeric channels show cooperativity,
which suggests a multimeric structure of the native channel.
The potent antagonists of native non-NMDA receptors,
CNQX and NBQX, exhibit no or only low selectivity for
different subunits. In situ hybridization studies have revealed
a widespread, but differential distribution of the GluR1-
GluR4 mRNAs.
Low-affinity KA receptors: GluR5-GluR7
When expressed in transfected cells, GluR5 can be activated
(in sequence of agonist potencies) by domoate>KA>Glu>
AMPA with rapid desensitization. The sequence of potency
for GluR6 is domoate>KA>quisqualate>Glu. The absence of
responses of GluR6 to AMPA demonstrates that AMPA is an
agonist at only a subset of ionotropic non-NMDA subunits.
In contrast with GluR1-GluR4, both GLU and KA desen-
sitize GluR5 and GluR6 receptors. The expression patterns
of GluR6 and GluR7 transcripts are clearly different from the
distribution pattern of [3H]AMPA in the brain, but they
overlap very well with most of the [3H]KA binding sites.
GluR6 responses can be increased by 50% by phospho-
rylation with protein kinase A (PKA). This modulatory effect
of PKA does not alter the affinity for Glu or the desen-
sitization properties. It has been shown that both AMPA and
kainate GluR5 receptors play an enhanced role in spinal
nociceptive processing following the development of periph-
eral inflammation, as antagonists at both receptors are more
effective against nociceptive responses, including wind-up,
under these inflammatory conditions (Stanfa and Dickenson
1999).
High-affinity KA receptors: KA1 and KA2
The affinities of KA1 and KA2 for KA (binding which is
inhibited by CNQX) are significantly higher than those of
GluR5-GluR7, suggesting that KA1 and KA2 may represent
the high-affinity [3H]KA receptor seen in ligand-binding
studies of synaptic membranes and in autoradiographic
studies of brain sections. The sequence of agonist potencies,
KA>quisqualate>domoate>Glu>>AMPA, also demonstrates
that KA1 and KA2 are pharmacologically distinct from
GluR5-GluR7 and are high-affinity KA receptors. When the
KA2 subunit is co-expressed with GluR6, the AMPA re-
sponse is nondesensitizing, which is quite different from the
AMPA currents of GluR1-GluR4. KA1 and KA2 RNAs are
distributed differently in the brain. Whereas KA1 RNA is
generally expressed at low levels and is abundant in only two
cell types, the CA3 pyramidal cells and the dentate granule
cells of the hippocampus, KA2 RNA is widely expressed in
most parts of the brain.
NMDA receptors: NMDAR1 and NMDAR2
When expressed in oocytes, homomeric NMDAR1 receptors
respond in the presence of glycine (Gly) to Glu, NMDA,
quisqualate, ibotenate, Asp, and L-homocysteic acid,but they
do not respond to KA, AMPA or trans-ACPD, or to Gly itself.
The competitive NMDA receptor antagonists D-APV, CPP,
CGS 19755 and 7-Cl-KYNA all inhibit NMDAR1 responses.
The channel blocker MK-801, Zn2+ and phencyclidine also
inhibit the receptor (Kovács and Larson 1994, 1997). These
data show that the functional properties that reported for the
NMDA receptors from studies on other systems can all be
found in NMDAR1. NMDAR1 RNA is expressed in almost
all neuronal cells, with particularly high levels in the cere-
bellum, hippocampus, cerebral cortex, and olfactory bulb.
Activators of protein kinase C (PKC) such as PMA produce
a 3- to 20-fold stimulation of the receptor response. PKA
activators such as 8-bromo-cAMP or forskolin, on the other
hand, do not alter the NMDAR1 receptor responses to
agonists. In contrast with NMDAR1, none of the NMDAR2
subunits assembles into functional ion channels when ex-
pressed as homomeric receptors. However, when co-ex-
pressed with NMDAR1, each of the four NMDAR2 subunits
co-assemble with NMDAR1 into functional heteromeric
receptor that have properties different from those of the
homomeric NMDAR1 receptor. The properties of the differ-
ent heteromeric channels are not equivalent. PKC activators
potentiate the responses of the NMDAR1/NMDAR2A and
NMDAR1/NMDAR2B, but not those of NMDAR1/
NMDAR2C receptors. PKC potentiation is sensitive to the
PKC inhibitor staurosporine.
Group I metabotropic Glu receptors: mGluR1
and mGluR5
When expressed in oocytes, both mGluR1 and mGluR5 re-
spond (in sequence of potency) to quisqualate>ibotenate~
Glu>trans-ACPD, producing large, long-lasting oscillating
currents. These currents are typical for receptors coupled to
phospholipase C (PLC), which releases Ca2+ from internal
stores via inositol phosphates (IP). EGTA injection selective-
ly inhibits mGluR1 responses, thereby demonstrating that
mere membrane depolarization is not sufficient to trigger
mGluR signal transduction pathways. Activation of mGluR1
or mGluR5 does not inhibit forskolin-induced cAMP forma-
tion, and is therefore not coupled to the inhibitory cAMP
cascade. Both mGluR1 and mGluR5 are widely expressed in
the brain, overlapping in most regions but also showing some
clear differences. The high level of mGluR1 mRNA expres-
sion in the hippocampal CA3 pyramidal neurons and cerebel-
lar Purkinje cells suggests that mGluR1 may be involved in
LTP at the mossy fiber-CA3 synapse and in long term depres-
sion (LTD) at the parallel fiber-Purkinje cells synapses, both
of which are pertussis toxin (PTX)-sensitive phenomena.
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Group II metabotropic Glu receptors: mGluR2-
mGluR4 and mGluR6
Upon expression in transfected cell lines, mGluR2 has been
shown to affect IP formation only slightly, but to inhibit
forskolin-induced cAMP formation markedly, an effect that
is inhibited by PTX in a dose-dependent manner. Thus,
mGluR2 appears to be coupled to the inhibitory cAMP
cascade via a PTX-sensitive G-protein. The rank order of
agonist potency for mGluR2 and mGluR3 is GLU~tACPD>
IBO>QA, whereas the rank order for mGluR4 is quite
different, AP4>GLU~IBO>tACPD. mGluR2 RNA is promi-
nently expressed e.g. in the Golgi cells of the cerebellum,
cortical neurons and intrinsic neurons of the olfactory bulb.
Increasing evidence also suggests an involvement of
mGluRs in nociception and pain behavior, although the
contribution of individual mGluR subtypes is not yet clear
(Budai and Larson 1998). It has been suggested that the
mGluR1 subtype is activated endogenously during brief
high-intensity cutaneous stimuli and is critically involved in
capsaicin-induced central sensitization (Neugebauer et al.
1999). Also, group I mGluRs (mGluR1 and mGluR5) may
act to enhance ionotropic Glu responses but the two types of
mGluRs may have different intracellular mechanisms of
action (Ugolini et al. 1999). Group I mGluR antagonists have
a significant antinociceptive efficacy in a mouse visceral pain
model (Chen et al. 2000). In addition to NMDA receptor,
metabotropic Glu receptor activation appears to be involved
in the generation of the segmental spinal reflex evoked by
high-intensity stimulation in the neonatal rat spinal cord in
vitro (Boxall et al. 1996).
Inhibitory Amino Acids (IAAs)
γ-Aminobutyric acid (GABA) and glycine
GABA and Gly along with their synthesizing enzymes, are
distributed broadly in the spinal cord. Both are candidate
inhibitory neurotransmitters in the dorsal horn as they
increase Cl- conductance through neuronal cell membranes
and hence produce inhibitory postsynaptic potentials.
GABAergic neurons are found throughout the gray matter
of the spinal cord, with a higher frequency in the superficial
laminae (laminae I-III) (Magoul et al. 1987; Todd and
Sullivan 1990; Powell and Todd 1992; Spike and Todd 1992;
Todd et al. 1992). Three GABA receptor subtypes have been
identified: the GABA
A
 receptor subtype, which mediates
rapid ionotropic transmission; the GABA
B
 receptor subtype,
which mediates a variety of metabotropic responses; and the
GABA
C
 subtype, which has not yet been found in the dorsal




receptor ligand binding in the dorsal horn. Both receptor
subtypes can be found in great numbers on the primary
afferent terminals. There is a heavy concentration of GABA
receptors exists in lamina II, and much thoughts has therefore
been given to the presynaptic modulation of the fine-caliber,
presumably nociceptive, primary afferent input. GABA
B
receptors are found in abundance in laminae I, III and IV, and
accordingly are thought to be involved in the presynaptic
control of Aδ and Aβ primary afferent fibers. Almost all cell
bodies in the DRG are positively stained with an antibody to
the subunits of the GABA
A
 receptors. Moreover, intrinsic
dorsal horn neurons contribute significantly to the GABA
A
receptor population in the dorsal horn. Baclofen, a chlorophe-
nyl derivative of GABA and selective ligand for GABA
B
receptors, depresses both monosynaptic and polysynaptic
transmission in the dorsal horn possibly through a decrease
in transmitter release rather than by any antagonism at




 sites, are present in high concentrations
in laminae I, II, III and IV of the dorsal horn and that after
the neonatal administration of capsaicin this binding is
reduced by 40-50% (Price et al. 1984).
Glycine immunoreactivity within the dorsal horn of the
rat spinal cord is relatively sparse in laminae I and II, but is
present in higher concentrations in lamina III and deeper
parts (Todd and Sullivan 1990). Gly-containing axons in
laminae I-III may be derived from various sources, such as
local interneurons, distant spinal cells or supraspinal neurons.
Glycinergic neurons in the dorsal horn may receive a signifi-
cant synaptic input from myelinated low-threshold mechano-
receptors (Todd 1991; Todd et al. 1991). Two types of Gly
receptors exist in the CNS, strychnine-sensitive and -insensi-
tive ones. In general, the strychnine-sensitive receptors
predominate in the dorsal horn. Gly receptors and GABA
A
receptors are often colocalized and the former are regarded
as being postsynaptic to primary afferent fibers. The strych-
nine-insensitive Gly modulatory binding site of the NMDA
receptor/channel complex may play a major role in the
regulation of NMDA receptor-mediated synaptic events
(Thomson 1990; Huettner 1991). Electrophysiological
studies on isolated systems have shown that Gly increases the
current evoked by NMDA, and it is absolutely required as a
co-agonist for NMDA receptor/channel activation (Johnson
and Ascher 1987; Kleckner and Dingledine 1988; Kushner
et al. 1988). Intrathecal application of 7-chlorokynurenate,
an antagonist at the allosteric Gly site associated with the
NMDA receptor, decreases the frequency-dependent potenti-
ation (wind-up) elicited by peripheral stimulation (Dickenson
and Aydar 1991). In behavioral experiments, the blockade of
strychnine-sensitive Gly receptors in the spinal cord unmasks
a facilitatory effect of Gly on NMDA-induced convulsions
(Larson and Beitz 1988). In intact animals, low doses of
iontophoretically administered Gly increase whereas high
doses of Gly inhibit the firing of single nociceptive neurons
in the dorsal horn of the spinal cord evoked by ionto-
phoretically applied NMDA. When inhibitory effects of Gly
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dominate, iontophoretic application of strychnine reveals a
facilitation of the NMDA responses by Gly (Budai et al.
1992a). In behavioral studies, NMDA, strychnine and bicu-
culline (a GABA
A
-receptor antagonist) produce similar
touch-evoked allodynia. It has been hypothesized that
GABA
A
 sites regulate presynaptic Glu release, while Gly
regulates the excitability of neurons postsynaptic to the
glutamatergic terminals (Ishikawa et al. 2000).
Peptides
Tachykinins: Substance P (SP) and Neurokinin A
(NKA)
The preprotachykinin A gene that encodes SP produces three
different messenger RNAs. They encode both SP and NKA
as they are synthesized from some of the same precursor
proteins (Helke et al. 1990). The mRNA for preprotachykinin
A gene occurs in small and medium-sized DRG nerve cells
(Boehmer et al. 1989). It is probable that the two tachykinins
coexist in many DRG neurons.
The interactions of EAAs and tachykinins, such as SP, in
spinal afferent and nociceptive processing are suggested by
several findings. SP and EAAs are found to be co-localized
in the central terminals of primary afferent neurons. SP
produces a long-lasting enhancement of the responses of
dorsal horn neurons to iontophoretically applied EAA
agonists. Combined treatment with SP and NMDA produces
a profound enhancement of the responses of the dorsal horn
neurons to nonnoxious and noxious mechanical stimulation,
as well as the behavioral responses. These effects probably
depend on both presynaptic and postsynaptic actions of SP
on EAA neurotransmission, since SP has been found to
enhance the release of Glu and Asp from the spinal dorsal
horn, whereas SP produces a potentiation of Glu and NMDA-
induced currents in spinal dorsal horn neurons in vitro. SP
is neither necessary nor sufficient to elicit pain at the spinal
level. On the basis of a detailed analysis of behavioral and
electrophysiological studies, a modulatory role of SP in
EAA-related nociceptive transmission has been postulated.
SP has also been proposed as the agent, which mediates the
slow temporal summation (wind-up) of C-afferent, evoked
responses in dorsal horn nociceptive neurons (Budai and
Larson 1996). It has been shown that SP enhances while the
SP antagonist DPDT-SP attenuates the prolonged discharge
of dorsal horn neurons evoked by repetitive stimulation of C-
afferents. Neither compound affects the A-fiber-evoked firing
or spontaneous cell activity, indicating that the effects of SP
are highly selective to C-fiber-mediated nociceptive trans-
mission (Kellstein et al. 1990). NKA is released from the
primary afferent terminals in response to the same mechan-
ical, thermal and chemical stimuli that release SP (Diez
Guerra et al. 1988; Duggan et al. 1990).
Neurokinin (NK) receptors consist of three categories:
NK-1, NK-2 and NK-3. The most widely studied of these is
the NK-1 receptor, often referred to as the SP receptor
(Polgár et al. 1999). SP exerts its effects on spinal cord
neurons primarily via NK-1 receptors and secondarily via
NK-2 receptors. These receptors have been cloned, se-
quenced and expressed in oocytes. The mechanism of action
of SP at these receptors involves the production of IP
3
 and
diacylglycerol (DAG) by activation of the enzyme phospho-
lipase C via PTX-insensitive G-proteins. This results in an
elevated intracellular Ca2+ level by promoting the release of
Ca2+ from intracellular stores. The activation of NK and/or
EAA receptors, may therefore lead to the activation of
various intracellular second messengers. These include
activation of (a) NO synthase and consequently NO synthe-
sis, which in turn activates soluble guanylate cyclase and
increases cGMP, (b) phospholipase A
2
, which triggers the
production of arachidonic acid, and (c) PKC via generation
of DAG. By immunohistochemistry, the heaviest immunore-
activity for NK-1 receptors is observed in the middle part and
lateral fourth of lamina I where the great majority of immu-
noreactive perikarya represents fusiform and multipolar cells.
In lamina II, the middle and medial part shows moderate
immunoreactivity, most of the cells resembles stalked cells.
In lamina III, the labeled perikarya are evenly distributed,
while those in lamina IV accumulates mainly in the lateral
part (Polgár et al. 1999). The activation of NK-1 receptors
is dependent on the C-terminal domain of SP and may be
responsible for most of the SP effects. The C-terminal
sequence of SP is also responsible for a series of immu-
nological events. By contrast, the N-terminal domain of SP
is involved in the modulation of catecholamine release from
adrenal chromaffin cells and in promoting histamine release
from peritoneal mast cells. Effects of SP that are independent
of NK receptors have also been reported. In rat peritoneal
mast cells, G-proteins may be activated through their direct
interaction with the cationic cluster of SP, which is located
at its N-terminus. These effects of SP are sensitive to PTX.
The N-terminal metabolic fragments of SP are reportedly
also active in spinal neurotransmission. A decreased behav-
ioral responsivity to repeated intrathecal (i.t.) injections of SP
appears to be brought about, at least in part, by the rapid
accumulation of N-terminal metabolites of SP (Larson 1988).
The major metabolite of SP appears to be the N-terminal
heptapeptide SP1-7. Exogenously administered SP1-7 inhibits
the excitatory behavioral effects of SP in the spinal cord
(Igwe et al. 1990a, 1990b, 1990c), and there is a strong
correlation between the accumulation of N-terminal frag-
ments of SP and the development of desensitization to the
behavioral effects of SP. Two binding sites for [3H]SP1-7
recently characterized in the mouse spinal cord may account
for the activity of SP N-terminal fragments. N-terminal
fragments of SP have also proven capable of altering high-
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affinity, ß-FNA-insensitive, µ-type opioid binding (Krumins
et al. 1989; Krumins et al. 1990). Iontophoretic application
of SP causes an increase in the response of the cells to
mechanical stimulation of the cutaneous receptive field,
which is generally accompanied by increases in the responses
to the EAAs. However, reciprocal changes caused by SP or
its N-terminal fragment SP1-7 in EAA responses have also
been reported (Budai et al. 1992b; Dougherty et al. 1993).
This type of change is characterized by decreases in the
responses to one class of EAA agonist (NMDA versus non-
NMDA), despite increases in the responses to the other type
of EAA (non-NMDA) agonist. Overall inhibitory effects of
SP on EAA responses are observed on occasion (Dougherty
et al. 1993). The reciprocal changes in EAA responses
following SP or SP1-7 application may represent a switching
of the dominant input to a particular cell from one type of
EAA receptor to another. It has been proposed that the
increases caused in the EAA responses by SP are due to the
activation of appropriately inter-linked receptor-mediated
events in particular dorsal horn neurons and that the second
messenger systems activated by the combination of NMDA
and SP are different from those activated by the combination
of non-NMDA EAAs and SP (Dougherty et al. 1993). An
alternative second messenger system could provide a mech-
anism for the reciprocal changes observed following co-
application of SP or SP1-7 and non-NMDA agonist, since
interregulatory effects between the EAA receptor subtypes
involve Ca2+ release.
The hypothesis that a SP antagonist may possess anal-
gesic activity in man remains to be proven. Antagonists that
are based on modifications of one or more of the 11 amino
acids that comprise SP possess poor pharmacokinetic prop-
erties and limited in vivo activities. However, during the past
decade, several nonpeptide, metabolically stable antagonists
have become available (Watling 1992). Behavioral studies
have shown that CP 96,345, a potent nonpeptide NK-1
antagonist, blocks the slow EPSP induced by noxious cuta-
neous stimulation and repetitive C-fiber stimulation, and
reduces noxious heat neuronal responses without effect on
innocuous inputs (Nagahisa et al. 1993). Unfortunately, CP
96,345 has been demonstrated to have nonspecific activity in
the formalin and carrageenan-induced models of nociception,
which is probably due to its affinity for the L-type Ca2+
channels. More recently, a new piperidine derivative, CP-
99,994, has been introduced and reported to have signifi-
cantly reduced affinity for the L-type Ca2+ channel. Another
potent, nonpeptide NK-1 receptor antagonist, RP 67580,
inhibits the first and second phases of the formalin response
in a dose-related manner. RP 67580 attenuates the facilita-
tion, but not the baseline, of a spinal flexor reflex by noxious
conditioning stimuli in the rat (Parsons et al. 1996). These
results support the hypothesis that NK-1 receptors play a role
in prolonged nociceptive transmission in the spinal cord.
Calcitonin gene-related peptide (CGRP)
CGRP occurs in highest concentration in the small DRG
nerve cells. Its two forms are encoded in two variants of
messenger RNA that are spliced from the same gene that
encodes calcitonin. Primary afferent neurons seem to be the
only source of CGRP in the dorsal horn (Tuchscherer and
Seybold 1989). The majority of primary afferent neurons
associated with pain transmission contains CGRP (Nasu
1999; Pezet et al. 1999). Immunoreactive CGRP is released
from the central processes of primary afferent neurons
following peripheral application of noxious thermal, me-
chanical and chemical stimuli (Morton and Hutchison 1989;
Garry and Hargreaves 1992). The discharge frequency of
wide dynamic range neurons in the dorsal horn decreases
significantly upon activation of CGRP receptors which may
play an important role in the transmission of the presumed
nociceptive information (Yu et al. 1999). Pronase-induced
deafferentation significantly increases CGRP binding in the
superficial (I-II) and deeper (II-IV) laminae of the dorsal horn
(Helgren et al. 1999). In mutant mice that lack αCGRP
mRNA, CGRP immunoreactivity is almost completely
absent from the spinal cord and is not observed at all in the
spinal ganglia. The antinociceptive behavior tested by the
tail-flick and hot-plate tests does not differ significantly in
mutant and wild-type mice, except when challenged by
morphine (Salmon et al. 1999).
Opioid peptides: enkephalins and dynorphins
Two classes of opioid peptides are present within the spinal
dorsal horn: the enkephalins: Met- and Leu-enkephalin and
Enk-8 (Met-enkephalin-Arg-Gly-Leu); and the dynorphins:
dynorphin A and dynorphin B. Enkephalin molecules are
derived from the precursor protein preproenkephalin (PPE),
whereas dynorphins are derived from a different precursor,
preprodynorphin (PPD) (Todd and Spike 1992, 1993). The
enkaphalins are the putative endogenous ligands for delta (δ)
opioid receptors. Dynorphin A is the endogenous ligand for
the kappa (κ) opioid receptors.
The importance of opioid receptors in the control of pain
and somatosensory processes is widely accepted and is of
significant clinical relevance. Their three major subtypes,
called mu (µ), delta (δ) and kappa (κ), are transmembrane G-
protein-coupled receptors. In the spinal dorsal horn, the most
prevalent type seems to be the µ (70% or more), with con-
siderably fewer δ (23% or less) and κ (7% or less) opioid
receptors (Gulya et al. 1986; Besse et al. 1990a, 1990b;
Stevens et al. 1991; Dado et al. 1993; Coggeshall and Carlton
1997). In ligand-binding experiments, each type is prefer-
entially located in the superficial laminae, laminae I-III. The
majority of the opioid receptors are located on fine primary
afferent fibers and terminals since dorsal rhizotomy causes
a significant loss in opioid receptor binding in the superficial
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dorsal horn (Stevens and Seybold 1995). The receptor loss
parallels the disappearance of the fine primary afferent fibers
after axotomy. However, much opioid ligand binding still
remains after dorsal rhizotomy and this residual binding is
regarded as being postsynaptic to the fine primary afferent
input (Gouarderes et al. 1985, 1986; Faull and Villiger 1987).
Two isoforms of the µ opioid receptor (MOR1 and MOR1B)
have recently been cloned (Schulz et al. 1998).
The dorsal horn regions that receive descending inputs
from the rostral ventromedial medulla (RVM) contain µ, δ
and κ opioid receptors, as well as enkephalinergic interneu-
rons and terminal fields (Besse et al. 1991; Fields et al. 1991;
Arvidsson et al. 1995a, 1995b; Mansour et al. 1995; Chieng
et al. 1996). RVM axon terminals contact enkephalinergic
dorsal horn neurons (Glazer and Basbaum 1984; Cho and
Basbaum 1989). Release of enkephalin at spinal levels has
been demonstrated (Bourgoin et al. 1988; Tang et al. 1989;
Yaksh and Chipkin 1989; Collin et al. 1992; Dado et al.
1993). Opioids directly inhibit primary afferent nociceptors
(Werz et al. 1987; Moises et al. 1994; Taddese et al. 1995)
and nociceptive dorsal horn neurons (Omote et al. 1990;
Glaum et al. 1994; Grudt and Williams 1994; Randic et al.
1995). Endogenous opioids acting via spinal µ opioid re-
ceptors contribute to brainstem control of nociceptive spinal
dorsal horn neurons. The inhibition appears to result in part
from presynaptic inhibition of afferents to dorsal horn
neurons (Budai and Fields 1998).
Recently, two endogenous peptides, endomorphin-1 and
endomorphin-2 (Zadina et al. 1997), specific for µ-opioid
receptors have been identified. Endomorphin-2-like immu-
noreactivity was found to be colocalized in a subset of SP-
and µ opioid receptor-containing fibers in the superficial
laminae of the spinal cord and spinal trigeminal nuclei.
Disruption of primary sensory afferents by mechanical
(deafferentation by dorsal rhizotomy) or chemical (exposure
to the primary afferent neurotoxin, capsaicin) methods
virtually abolishes endomorphin-2-like immunoreactivity in
the dorsal horn. These results indicate that endomorphin-2 is
present in primary afferent fibers where it can serve as the
endogenous ligand for pre- and postsynaptic µ receptors and
as a major modulator of pain perception (Martin-Schild et al.
1998; Martin-Schild et al. 1999). Intrathecal application of
endomorphin-1 and endomorphin-2 increases the tail-flick
latency and, to the lesser extent, the paw pressure latency
(Przewlocka et al. 1999). The formalin-induced behavior is
attenuated by endomorphins, and endomorphins antagonize
allodynia in a dose-dependent manner (Przewlocki et al.
1999).
Nociceptin (orphanin FQ) and nocistatin
Nociceptin (orphanin FQ), the natural agonist of orphan
opioid receptor-like receptor (ORL-1), is a heptadecapeptide
that is endowed with supraspinal pronociceptive activity in
vivo. Via ORL-1 receptors, nociceptin FQ triggers the same
G-protein-mediated signaling pathways, as do opioids,
however, to produce pharmacological effects that sometimes
differ from, and even oppose those of opioids (for reviews see
Darland et al. 1998; Yamamoto et al. 1999). Nociceptin
stimulates an outward K+ current and/or inhibits voltage-
gated Ca2+ channels, thereby reduces synaptic efficacy, i.e.
neuronal activity. Nociceptin is derived from a larger precur-
sor, prepronociceptin (PPNOC). The entire coding sequence
of the precursor protein has been cloned for nociceptin. The
deduced nociceptin precursor shows sequence similarity to
the opioid peptide precursors and shares characteristic
structural features particularly with preprodynorphin. In situ
hybridization analysis of nociceptin precursor mRNA in the
mouse central nervous system reveals that it is highly
expressed in discrete neuronal sites with the pattern distinct
from those of opioid peptides (Houtani et al. 1996). No-
ciceptin and its precursor mRNA are present in a number of
brain regions, less abundant in the spinal cord, and negligible
in the cerebellum. In situ hybridization analysis reveals that
hybridization-positive neurons are distributed in the su-
perficial layer (lamina I) of the dorsal horn and are also
interspersed between the tract of Lissauer in the spinal cord
(Okuda-Ashitaka et al. 1996). Combined in situ hybridization
and immunohistochemistry have shown a correlation be-
tween nociceptin immunoreactivity and PPNOC mRNA. In
the spinal cord, nociceptin is observed throughout the dorsal
and ventral horns (Neal et al. 1999). By using double label
immunohistochemistry and confocal microscopy, the co-
localization of µ opioid receptors and ORL-1 receptors is not
observed in either perikarya or neuropil in the DRG, the
Lissauer’s tract or in the superficial laminae of the spinal
cord. Likewise, there is no evidence for co-localization of
these receptors within the periaqueductal gray, the nucleus
raphe magnus, the gigantocellular reticular nucleus, and the
nucleus of the solitary tract. These observations indicate that
µ opioid and ORL-1 receptors are expressed predominantly
on different fiber systems in these regions (Monteillet-Agius
et al. 1998).
Antinociceptive effects for nociceptin have been reported
in spinal applications. Nociceptin dose-relatedly inhibits the
C-fiber evoked wind-up and post-discharge of dorsal horn
neurons, but not the baseline C-fiber-evoked responses. The
antinociceptive role of nociceptin in the spinal cord differs
from that of classical opioids (Stanfa et al. 1996). Intrathecal
nociceptin produces dose-dependent depression of a spinal
nociceptive flexor reflex and behavioral antinociception in
the tail flick test with no signs of sedation or motor impair-
ment (Xu et al. 1996). Intrathecally administered nociceptin
depresses both the phase 1 and phase 2 flinching behavior in
the formalin test and depresses the level of thermal hyper-
algesia in a dose-dependent manner (Yamamoto et al. 1997).
It is of interest to note that intracerebroventricular application
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of nociceptin, in contrast with intrathecal administrations,
enhances the formalin-induced pain behavior (Wang et al.
1999). Nociceptin elicits a rapidly appearing, naltrexone-
reversible, dose-dependent analgesia in the tailflick assay
without any indication of hyperalgesia. Blockade of sigma
receptors with haloperidol enhances the analgesic potency of
spinal nociceptin, but not as dramatically as supraspinal
nociceptin (King et al. 1997). Intrathecal nociceptin dose-
dependently alleviates mechanical and cold allodynia-like
behavior in two models of neuropathic pain (Hao et al. 1998).
Whole-cell recordings from substantia gelatinosa neurons in
transverse lumbar spinal cord slices show that exogenous
nociceptin, at low concentrations, depresses excitatory
postsynaptic potentials evoked by stimulation of dorsal
rootlets or, at high concentrations, it hyperpolarizes substan-
tia gelatinosa neurons and suppresses spike discharges. The
latter actions are not reversed by the known opioid receptor
antagonist, naloxone. It is concluded that nociceptin-like
peptide is concentrated in nerve fibers of the rat dorsal horn
and that it may serve as an inhibitory transmitter within the
substantia gelatinosa (Lai et al. 1997). It has also been shown
that nociceptin inhibits excitatory synaptic transmission in
the superficial layers of the rat dorsal horn by acting on
presynaptic, presumably ORL-1 receptors (Liebel et al.
1997). Nociceptin primarily inhibits EAA (Glu, KA and
quisqualate)-induced currents in isolated rat spinal dorsal
horn neurons via non-opioid mechanisms (Shu et al. 1998).
Recently, the introduction of two selective and competitive
nociceptin receptor antagonists has been reported: one
peptide analog (Calo et al. 2000) and one nonpeptidyl in
nature (Ozaki et al. 2000). However, the peptide ORL-1
receptor antagonist [Phe1 psi(CH2-NH)Gly2]nociceptin-(1-
13)-NH2, may act as a nociceptin agonist in the rat spinal cord
(Carpenter and Dickenson 1998).
The nociceptin precursor protein contains another biolog-
ically active peptide, which is termed nocistatin and is isolat-
ed from bovine brain. Nocistatin blocks nociceptin-induced
allodynia and hyperalgesia, and attenuates pain evoked by
prostaglandin E2. Intrathecal pretreatment with antinocistatin
antibody decreases the threshold for nociceptin-induced
allodynia. Although nocistatin does not bind to the nociceptin
receptor, it binds to the membrane of mouse brain and of
spinal cord with high affinity. Nociceptin and nocistatin pep-
tides may play opposite roles in pain transmission (Okuda-
Ashitaka et al. 1998). It is suggested that nociceptin may be
involved in the second phase of the mouse formalin test and,
under such pathophysiological conditions, nocistatin can
exhibit antagonism against nociceptin at the spinal level
(Nakano et al. 2000). Nocistatin induces a moderate facilita-
tion of the flexor reflex without producing reflex depression.
It interacts with nociceptin in a complex fashion, increasing
excitation and reducing inhibition (Xu et al. 1999).
Biogenic amines
Serotonin (5-HT)
5-HT is present in the axons and terminals of raphe-spinal
neurons in the dorsal horn, especially in the superficial
laminae, laminae I-III. The origin of serotonergic projection
to the dorsal horn is mainly the nucleus raphe magnus
(Dahlström and Fuxe 1965; Basbaum et al. 1978; Miletic et
al. 1984). 5-HT and several peptides, including SP, CGRP,
enkephalins and somatostatin, may be co-localized in the
same raphe neurons and in their terminals. 5-HT may also be
co-localized with GABA (Millhorn et al. 1987a, 1987b).
Molecular cloning has identified seven distinct families of 5-
HT receptors (5-HT1-7). The 5-HT3 family consists of ligand-
gated ion channel receptors. The other 6 families interact
with G-proteins and are coupled to second messengers. Three
5-HT receptor subtypes influence the dorsal horn soma-
tosensory processing: 5-HT1, 5-HT2, and 5-HT3. There are
three major sources of 5-HT receptors to the spinal cord
dorsal horn: the DRG cells, the intrinsic spinal neurons and
the descending systems. Neonatal capsaicin treatment or
dorsal rhizotomy decrease 5-HT1A and 5-HT3 receptor bind-
ing in laminae I and II, but some still remains, indicating both
pre- and postsynaptic localizations. A large majority of the
5-HT receptors in the dorsal horn do not participate in classic
synapses, but are found in extrasynaptic sites along the
dendrites and somas.
The activation of 5-HT receptors can produce multiple
physiological events, since 5-HT receptor families can either
promote or inhibit different second messenger systems.
Intrathecally administered 5-HT can either inhibit (Hylden
and Wilcox 1983) or stimulate (Hylden and Wilcox 1983;
Clatworthy et al. 1988) nociceptive reflexes. Iontophoretic
application in the vicinity of dorsal horn neurons generally
causes inhibition (Griersmith and Duggan 1980), although
excitatory effects have also been reported (Todd and Millar
1983). It has been suggested that the 5-HT1B and 5-HT1D
receptor subtypes mediate selective inhibition of nociceptive
neurons, whereas 5-HT1A agonists facilitate nociceptive
responses (El-Yassir et al. 1988; Alhaider and Wilcox 1993).
Spinal 5-HT3-mediated analgesia involves GABA receptors,
probably through the excitation of GABAergic interneurons
(Alhaider et al. 1991).
Norepinephrine (NE)
The activation of α2-adrenergic receptors in the dorsal horn
of the spinal cord produces powerful analgesia in humans and
animal models. There is a dense concentration of both
noradrenaline (Dahlström and Fuxe 1965) and α2-adrenergic
receptors in the dorsal horn (Young and Kuhar 1980; Jones
et al. 1982; Unnerstal et al. 1984; Nicholas et al. 1993;
Roudet et al. 1993). Although there are no noradrenergic
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neurons in the rostral-ventromedial medulla (RVM) or
periaqueductal gray (PAG), there is evidence that brainstem
noradrenergic neurons contribute to the PAG-RVM inhibition
of spinal nociceptive transmission. The adrenergic innerva-
tion of the spinal cord dorsal horn arises from the A5, the
locus coeruleus and the A7 noradrenergic cell groups in the
pons (Westlund et al. 1982; Schroder and Skagerberg 1985;
Proudfit 1988; Clark and Proudfit 1993). There is a projec-
tion from the rostral PAG to A5 (Kwiat and Basbaum 1990),
A7 and to locus coeruleus (Cameron et al. 1995), and a dense
projection from the RVM to the A7 noradrenergic cell group
(Clark and Proudfit 1993; Holden and Proudfit 1998). There
is behavioral and electrophysiological evidence that brain-
stem NE neurons contribute to the pain-modulating action of
the PAG-RVM-dorsal horn pathway. Direct spinal application
of adrenergic agonists produces behavioral analgesia (Reddy
et al. 1980; Barbaro et al. 1985) and inhibition of dorsal horn
neurons through α2-adrenergic receptors. Dorsal horn micro-
iontophoresis of selective α2-adrenoceptor antagonists, but
not the selective α1 antagonists, significantly reverses the
descending inhibition originating from the PAG. At low
ejection currents, clonidine, an α2 adrenoceptor agonist
markedly reduces noxious heat-evoked responses but has no
consistent action on the responses to iontophoresed EAAs
(NMDA or KA). At ejection currents higher than those
required to block descending inhibition, idazoxan potentiates
responses to both heat and EAA iontophoresis. At higher
ejection currents, EAA responses are inhibited by clonidine.
This indicates that both presynaptic and postsynaptic α2
receptors are involved in the inhibition of the recorded
neurons (Budai et al. 1998).
Neurons in DRG which give rise to primary afferent
fibers contain all three α2-adrenergic receptor subtypes (α2a,
α2b and α2c) mRNAs (Nicholas et al. 1993; Nicholas et al.
1996; Gold et al. 1997). The superficial layers of the spinal
dorsal horn, where nociceptive primary afferent fibers
terminate most densely, contain dense α2-adrenoceptor
binding, whereas only a small number of dorsal horn cells
contain α2-adrenoceptor mRNA. Noradrenaline or clonidine
significantly reduces the evoked release of Glu from spinal
cord synaptosomes (Kamisaki et al. 1993) and the release of
SP-like material and CGRP from spinal cord slices (Bourgoin
et al. 1993). It has been demonstrated that the α2a adreno-
ceptor subtype is the primary mediator of α2 adrenergic spinal
analgesia and is necessary for analgesic synergy with opioids
(Stone et al. 1997; Stone et al. 1998). Immunoreactivity (IR)
for both receptor subtypes has been observed in the super-
ficial layers of the dorsal horn of the spinal cord. The primary
localization of the α2a adrenoceptor in the rat spinal cord is
on the terminals of capsaicin-sensitive, SP-containing
primary afferent fibers. α2c Adrenoceptor-IR does not appear
to colocalize with the NK-1 receptor, nor is it localized on
astrocytes, as evidenced by a lack of co-staining with the glial
marker GFAP. However, some co-localization is observed
between α2c adrenoceptor-IR and enkephalin-IR, suggesting
that the α2c adrenoceptor may be expressed by a subset of
spinal interneurons. Interestingly, neither subtype is detected
on descending noradrenergic terminals (Stone et al. 1998).
Dopamine (DA)
There is more noradrenaline than dopamine in the spinal cord
(Fleetwood-Walker and Coote 1981). Both arise from su-
praspinal neurons. The dopaminergic projections to the
dorsal horn originate from the A11 cell group in the dien-
cephalon (Skagerberg and Lindvall 1985). Dopamine D2
receptor ligand binding is concentrated in the superficial
dorsal horn, chiefly in laminae II and III (Bouthenet et al.
1987; Yokoyama et al. 1994). Focal electrical stimulation in
the region of the A11 dopamine cell group selectively
suppresses the nociceptive responses of spinal, multire-
ceptive neurons in the rat. Iontophoretically applied dopam-
ine D2 receptor agonists cause selective inhibition of the
responses to noxious stimuli of the dorsal horn neurons,
whilst the spontaneous activity is unaffected (Fleetwood-
Walker et al. 1988).
Acetylcholine (ACh)
Choline acetyltransferase, the marker enzyme for cholinergic
neurons which synthesizes ACh, is abundant in the spinal
dorsal horn, especially in the superficial laminae (Kása and
Morris 1972; Kimura et al. 1981; Barber et al. 1984; Kása
1986; Phelps et al. 1988; Houser 1990; Ribeiro-da-Silva and
Cuello 1990; Todd 1991). Choline acetyltransferase has not
been found in DRG cells or in their axons (Barber et al. 1984;
Borges and Iversen 1986). Acetylcholinesterase, the enzyme
which removes ACh by hydrolysis, has also been localized
in the dorsal horn, with highest concentrations in laminae I-
III (Kása 1986). Radioactive nicotinic ACh receptor ligands
preferentially bind to the substantia gelatinosa, laminae II-
III or IV, with the emphasis on laminae III and IV (Wamsley
et al. 1981a; Gillberg and Aquilonius 1985; Gillberg and
Wiksten 1986). It is not clear whether nicotinic ACh recep-
tors are restricted to any particular cell type or sensory
modality. Muscarinic ACh receptors are concentrated in the
superficial layers of the dorsal horn, especially in laminae II
and I, and may be associated with fine-caliber afferent inputs.
Both nicotinic and muscarinic ligands bind to DRG cells and
dorsal rhizotomy significantly reduces their binding sites in
the dorsal horn (Wamsley et al. 1981a, 1981b; Seybold and
Elde 1984; Seybold 1985). Accordingly, a significant number
of dorsal horn ACh receptors are thought to be situated on
the primary afferent terminals.
In early studies, iontophoretically applied ACh was found
to depress the responses of dorsal horn interneurons to EAAs
(Curtis et al. 1966) or to evoke either excitation or depression
30
Budai
(Weight and Salmoiraghi 1966; Curtis 1967). Later, it was
shown that cholinergic compounds can depolarize one set of
dorsal horn neurons and hyperpolarize others in slice prepa-
rations (Urban et al. 1989). These effects are mediated by
both nicotinic and muscarinic receptors. Muscarinic antag-
onists interfere with the descending inhibition of dorsal horn
neurons produced by stimulation of the medial medulla
(Zhuo and Gebhart 1990a, 1990b). The analgesic effect of
intrathecally administered clonidine on neuropathic pain is
mediated, in part, by an increased ACh release which acti-
vates spinal muscarinic and nicotinic receptors. Spinally
released ACh, therefore plays a role in the antiallodynic effect
of intrathecally administered clonidine in neuropathic pain
(Pan et al. 1999).
Nicotine exerts antinociceptive effects by interacting with
one or more of the subtypes of nicotinic ACh receptors. Mice
lacking the α4 subunit of the neuronal nicotinic ACh re-
ceptors no longer express high-affinity [3H]nicotine and
[3H]epibatidine binding. These mutant mice display a re-
duced antinociceptive effect of nicotine in the hot-plate test,
and diminished sensitivity to nicotine in the tail-flick test
(Marubio et al. 1999). Epibatidine, a potent agonist for
neuronal nicotinic ACh receptors sharing similar structural
and functional characteristics with ACh and nicotine, was
used in this study. Analgesia through the activation of
muscarinic ACh receptors may occur in animal models of
acute noxious stimulation and of chronic hypersensitivity
pain (Eisenach 1999). It has been shown that presynaptic M3
muscarinic receptors in the spinal cord are involved in the
second phase of nociception induced by formalin injection
into the paw (Honda et al. 2000).
ATP and adenosine receptors
The role of ATP as a putative neurotransmitter in the medi-
ation of nociceptive has been intensely investigated. ATP has
been found to excite some dorsal horn neurons and to
potentiate their responses to NMDA (Jahr and Jessell 1983).
This action of ATP is likely to take place through activation
of the ionotropic P2X receptor family which may be located
both on intrinsic dorsal horn neurons and on the central
terminals of fine primary afferent fibers. In fact, the activation
of presynaptic P2X receptors in the dorsal horn has been
shown to evoke the release of Glu from cultured DRG cells
(Gu and MacDermott 1997). Further, P2Y receptors, a family
of metabotropic receptors (acting through PLC) activated by
the endogenous ligand ATP, have been demonstrated to
increase the EAA-mediated transmission in the dorsal horn
(Li and Perl 1995). The superficial layers of the spinal cord
dorsal horn express P2X2, P2X4, and P2X6 subunits entering
into the formation of ionotropic (P2X) receptors for ATP.
ATP reversibly increases the amplitude of electrically evoked
GABAergic IPSCs and reduces paired-pulse inhibition or
facilitation without affecting the IPSC kinetics. This effect
is preferentially, but not exclusively, observed in neurons co-
releasing ATP and GABA (Hugel and Schlichter 2000).
Spinal endogenous ATP may play a role in formalin- and
capsaicin-induced neurogenic pain via the P2X receptors
(Tsuda et al. 1999).
ATP is rapidly metabolized to adenosine which in turn
may activate a variety of adenosine (mainly A1 and A2)
receptors in the dorsal horn. Adenosine and ATP exert
multiple influences on pain transmission at peripheral and
spinal sites (Sawynok 1998). At peripheral nerve terminals
in rodents, adenosine A1 receptor activation produces
antinociception by decreasing, while adenosine A1 receptor
activation produces pronociceptive or pain-enhancing prop-
erties by increasing, cAMP levels in the sensory nerve
terminal. Adenosine A3 receptor activation produces pain
behaviors due to the release of histamine and 5-HT from mast
cells and subsequent actions on the sensory nerve terminal
(Gu and MacDermott 1997). It is most probable that adenos-
ine is most effective as an inhibitor of dorsal horn neuronal
activation mediated via non-NMDA EAA or SP receptors
(Keil and Delander 1995).
Nitric oxide (NO)
Nitric oxide (NO) has been characterized as a neuronal
messenger involved in a variety of neurotransmitter functions
(Bredt and Snyder 1992; Snyder 1992; Meller and Gebhart
1993; Zorumski and Izumi 1993). The production of NO
from the amino acid L-arginine (Arg) is catalyzed by a Ca2+
and calmodulin-dependent enzyme, NO synthase, which can
be selectively inhibited by structural analogs of Arg, e.g., NΩ-
nitro-L-arginine methyl ester (L-NAME). The enzyme NO
synthase has been localized within the spinal cord (Val-
tschanoff et al. 1992a, 1992b; Lee et al. 1993; Saito et al.
1994). NO is a small, reactive, lipophilic molecule with a
half-life of milliseconds to several seconds. It may act in the
neuron where it is produced, or diffuse through cell mem-
branes to act on adjacent cells as an intercellular messenger
(Garthwaite et al. 1988; Schuman and Madison 1994). The
properties of NO may allow it to act as a “retrograde trans-
mitter”, i.e. when produced in a postsynaptic neuron, NO
might diffuse to presynaptic sites, thereby altering the
presynaptic function (Baringa 1991). This concept is partic-
ularly favored in studies of LTP, where it may account for the
use-dependent changes in the efficacy of synaptic trans-
mission. The increase in intracellular level of Ca2+ triggers
a cascade of events that include stimulation of phospho-
lipases to produce DAG and ecoisanoids, stimulation of the
production of IP3, activation of PKC and activation of the
constitutive form of NO synthase. Allowing Ca2+ to enter the
neuron, NMDA receptor activation results in an increase in
production of NO, which diffuses to its site of action. Here,
it activates soluble guanylate cyclase, which in turn increases
the intracellular content of cGMP (Garthwaite et al. 1988).
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It has been shown that the amount of intracellular Ca2+
produced by NMDA receptor activation is sufficient to
prevent the activation of soluble guanylate cyclase by NO in
the neuron where it is synthesized (Knowles et al. 1990;
Vincent and Hope 1992). It has therefore been proposed that
NO must diffuse to adjacent, cells where soluble guanylate
cyclase is activated to increase the intracellular content of
cGMP. Evidence that hemoglobin, which binds extracellular
NO, prevents LTP supports this hypothesis (O’Dell et al.
1991; Schuman and Madison 1991).
Considerable evidence suggests that NO plays a role in
spinal somatosensory processing. The NMDA receptor
subtype, activated by endogenous agonists such as L-gluta-
mate, L-aspartate or L-homocysteate, appears to be involved
in multisynaptic nociceptive transmission and plasticity in
the spinal cord (for reviews see Wilcox 1991; Meller and
Gebhart 1993; Wilcox 1993; Wilcox and Seybold 1997).
Intrathecal administration of NMDA elicits a transient
hyperalgesia, which is inhibited by prior treatment with
L-NAME, methylene blue or hemoglobin (Kitto et al. 1992).
Intrathecal injection of NO-donating compounds such as
L-arginine, sodium nitroprusside or hydroxylamine also
results in hyperalgesia (Kitto et al. 1992; Meller et al. 1992a,
1992b; Meller and Gebhart 1993). In the formalin pain
model, inhibition of NO synthase by L-NAME produces
long-lasting antinociception (Moore et al. 1991). Topical
application of L-NAME onto the spinal cord attenuates both
the first and second peaks of the neuronal responses to
formalin (Haley et al. 1992). L-Arginine, which surprisingly
is antinociceptive itself, reverses the antinociceptive effects
of L-NAME in the formalin-induced paw licking test (Moore
et al. 1991), but not the decrease in neuronal firing rate
caused by L-NAME (Haley et al. 1992). L-Arginine, a
constituent amino acid of kyotorphin (L-tyrosyl-L-arginine),
an endogenous Met-enkephalin releaser in the brain and
spinal cord, is considered to be an effective kyotorphin
precursor. It has been proposed that L-arginine plays a dual
role in nociceptive processing, being antinociceptive via the
kyotorphin-Met-enkephalin pathway and nociceptive via the
L-arginine-NO pathway (Kawabata et al. 1993).
In in vivo electrophysiological studies, inhibition of NO
synthase by L-NAME has been reported to reduce the
responses of single dorsal horn neurons to the electrical or
chemical nociceptive stimulation of peripheral nerves (Haley
et al. 1992) and it selectively inhibits the responses of these
cells to iontophoretically applied NMDA (Radhakrishnan
and Henry 1993). Iontophoretically applied L-NAME causes
reciprocal changes in EAA responses: the NMDA-evoked
responses are significantly decreased, whereas the responses
to the iontophoretically applied non-NMDA agonists (AMPA
and KA) are increased (Budai et al. 1995). Intravenous
application of L-NAME suppresses ongoing activity record-
ed from dorsal rootlets that are responsive to electrical
stimulation of the axotomized sciatic nerve. This effect of L-
NAME is reversed by L-arginine (Wiesenfeld-Hallin et al.
1993). In vivo electrochemical studies have shown that NO
is released from substantia gelatinosa cells upon electrical
stimulation. NO release in the dorsal horn is significantly
decreased in animals treated with capsaicin for C-fiber
denervation (Kimura et al. 1999). Activation of Glu (NMDA)
receptors may account for the release of NO (Rivot et al.
1999). Neuronal NO synthase mRNA is upregulated in rat
sensory neurons after spinal nerve ligation (Luo et al. 1999).
Experimental data also suggest that NO contributes to the
development and maintenance of central sensitization of
spinothalamic tract cells and to the resultant mechanical
hyperalgesia and allodynia after peripheral tissue damage or
inflammation (Lin et al. 1999). Involvement of NO in the de-
velopment of central sensitization may affect nociceptive
processing by increasing Fos expression. Since many other
substances which are related to pain mechanisms can be in-
duced by Fos, it is suggested that nitric oxide may regulate
production of these substances through activation of Fos (Wu
et al. 2000).
Capsaicin and vanilloid receptors
Capsaicin (8-methyl-N-vanillyl-6-noneamide), the main
pungent ingredient in “hot” peppers, evokes a sensation of
burning pain by selectively activating C-polymodal noci-
ceptors (but not mechanoreceptors or cold receptors) that
convey information about noxious stimuli to the central
nervous system (Jancsó et al. 1977; Bevan and Szolcsányi
1990). At low concentrations, capsaicin selectively desen-
sitizes nerve fibers to subsequent stimuli in adult neurons.
Experimentally, spinal dorsal horn cells show two types of
excitatory responses to intradermal injection of capsaicin.
The first excitatory response shown by the majority of wide
dynamic range and nociceptive specific cells is consistent
with their sensitization by capsaicin. The cells produce an
acute and prolonged increase in ongoing activity with
capsaicin injection. Responses to mechanical stimuli are
substantially increased after capsaicin and an expansion of
receptive field is often observed. The responses of the same
cells to EAA agonists applied locally by iontophoresis are
also increased (Dougherty et al. 1999). At high concentra-
tions in newborn animals, capsaicin selectively degenerates
primary afferent C-fibers and a subset of small primary sen-
sory neurons within the DRG. The neurotoxic effect may
result from the rise in the concentrations of intracellular Ca2+
(Jancsó et al. 1977, 1984) as a consequence of the activation
of nonspecific cation channels by capsaicin. Systemic appli-
cation of capsaicin as an analgesic is unattractive because of
its extensive activation of C-polymodal nociceptors, yet there
may be therapeutic value in desensitization of nociceptors by
local application of capsaicin-related compounds (the ul-
trapotent resiniferatoxin; Szállási and Blumberg 1996).
32
Budai
[3H]Resiniferatoxin autoradiography reveals high densi-
ties of capsaicin binding sites in rat DRG as well as in the
superficial dorsal horn of the spinal cord, known to contain
the cell bodies and central terminals, respectively, of capsa-
icin-sensitive, sensory neurons (Szállási et al. 1994a, 1994b).
Capsaicin binds to a specific binding site that opens a
nonselective cation channel that is voltage-independent and
structurally related to members of the TRP family of ion
channels. The cloned capsaicin receptor, also termed as the
vanilloid receptor subtype 1 (VR1) (Szállási and Blumberg
1999), is also activated by increases in temperature in the
noxious range and by protons, suggesting that it functions as
a transducer of painful thermal or chemical stimuli in vivo
(Caterina et al. 1997). As revealed by mRNA distribution
studies, the VR1 vanilloid receptor subtype is expressed not
only in primary sensory neurons but also in several brain
nuclei (Mezey et al. 2000). There are indications that cannab-
inoids may be the endogenous ligands for the VR1 capsaicin
receptor (Szolcsányi 2000).
Conclusions
Somatosensory processing in the dorsal horn of the spinal
cord implicates the role of the same transmitters and re-
ceptors sub-serving neurotransmission in other areas of the
central and peripheral nervous systems. Transmitters released
from primary afferent fibers interact with receptors located
on secondary neurons in the dorsal horn of the spinal cord
and/or with receptors located on terminals of descending
axons and primary afferent fibers including the ones from
which they were released (autoreceptors). Many observations
support the concept that the afferent terminal may release
more than one transmitters when depolarized. A number of
transmitters involved (some 18 reviewed here) including
simple molecules such as EAAs whose rapid actions are in
the millisecond time range as well as complex molecules
such as peptides, which have effects lasting for seconds to
minutes or longer. The spinal dorsal horn is a primary
receiving area for somatosensory input and contains high
concentration of various receptors. These receptors show a
great deal of variety and mediate a number of cellular actions
and, thus, determine the neural response to the synaptic input.
The complex combination of neurotransmitters involved and
the modes of interactions among them make the dorsal horn
an obvious choice to produce analgesia.
Many neurons within the dorsal horn respond to noxious
stimuli. EAAs, especially AMPA and KA receptors, are
associated with the fast excitatory neurotransmission be-
tween nociceptors and spinal neurons. The AMPA compo-
nent of the Glu action requires less than a millisecond. This
is probably followed by the activation of NMDA receptors
whose activation is contingent on prior depolarization and
whose actions last for several tens of milliseconds. The
perception of pain requires consideration of events taking
place on an even longer time scale such as seconds, minutes
and hours. Activation of metabotropic receptors that act via
intracellular second messenger systems, e.g. neurokinin or
metabotropic Glu receptors, has been implicated in longer
term changes in the responsiveness of dorsal horn neurons.
It is hypothesized that an appropriate combination of several
afferent excitatory actions with an appropriate temporal
distribution could explain progressive development of
abnormalities in various pain states (reviewed by Wilcox
1991). It is noteworthy that the number of inhibitory neu-
rotransmitters and receptors greatly outnumbers the excita-
tory ones in the dorsal horn. It seems probable that trans-
mission of the somatosensory information from the primary
afferent fibers to the secondary dorsal horn neurons depends
on the complex interaction between the excitation by EAAs
and the inhibitory actions of several other transmitter sys-
tems.
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